OncoMethylome Sciences to Profile DNA for Abbott Oncology Compounds
"We are very pleased to add this collaboration to existing similar agreements and to use our high-throughput methylation platform to efficiently test our methylation biomarkers on biological samples provided by Abbott", commented Dr. Jim DiGuiseppi, Chief Technology Officer of OncoMethylome. "We are pleased that Abbott has chosen OncoMethylome and our methylation technology for this collaboration"
Financial details of the agreement were not disclosed
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.